MTM1 and neoplasm: This synergistic hyperactivation of proliferative and inflammatory pathways aligns with clinically aggressive tumor phenotypes, suggesting that MTM1-enriched malignant cells may represent a therapeutically targetable subpopulation primed for triaptosis induction.